Back to Agenda
Session 7: Innovation in the Pharmaceutical Sector
Session Chair(s)
Inas Chehimi
Head RA Middle East & North Africa
Novartis Pharma Services AG, United Arab Emirates
Nadine Otin
President
PHARMAREG International Consulting, France
This session will present the future of innovative medicine and its value from different perspectives: • The innovation in development of new therapies, real world evidence (RWE), novel endpoints (with regard to the development of oncology, neuroscience and diabetes, novel study designs) and benefits of the changes and cooperation between industry and regulators to regulate it; • Sharing a global overview of the research pipeline and provide more insights about what will come next, highlighting clearly the critical role of an efficient regulatory environment; • Discuss the value of innovation in the emerging market (patient quality of life, cost effectiveness, disease burden management/hospitalisation, social impact, competitiveness, etc).
Speaker(s)
Hajed M.H Hashan
Gulf Health Council, Saudi Arabia
Deputy of General Director
Value of Innovation
Frank R. Lichtenberg, PhD
Columbia University, Finance and Ecomomics Division, United States
Courtney C. Brown Professor of Business
Value of Innovation and Competitiveness of the Regulatory Environment
Jeffrey Kemprecos
Glaxosmithkline, United Arab Emirates
CGA Director-Gulf
Hend Al-Hussieny
Egyptian Drug Information Centre (EDIC), Egypt
Head
Have an account?